Dry Mouth: The Silent Epidemic and GLP-1 Medications & Oral Health—What You Must Know
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro, etc.) cause xerostomia in up to 40% of users, raising caries, candidiasis, and perio risk for the millions of dental patients now on these meds—clinics seeing a spike in restorative needs and recall frequency.
Key points
- CDC data cited: 72.4% of U.S. adults overweight/obese; roughly 1 in 8 adults now prescribed a GLP-1 drug for diabetes or weight loss.
- Xerostomia onset occurs within 4–8 weeks of initiation; saliva flow can drop 30–50% while patients remain on therapy for 12–24 months or longer.
- Dental implications: higher root caries rates, accelerated perio breakdown, and increased candidiasis—especially in older adults or those with existing restorations.
- Action for practices: add GLP-1 medication screening to medical history, schedule 3–4 month recalls, and stock OTC saliva substitutes/pH-neutral rinses for chairside dispensing.
Who should care
Read the original on Dentistry Today
Full reporting and any paywall content live on dentistrytoday.com. We summarize and score; we do not republish.
Related
- ·Regulatory
B.C. regulator warns Vancouver man offered illegal dental services in residential building
- ·Regulatory
New York City dental practices named in deceptive treatment financing lawsuit
- ·Regulatory
Texas DSO hit with cyberattack affecting 30,000 individuals
- ·Business
U.S. dental M&A begins to rebound as practice consolidation advances